Abstract | BACKGROUND: Intrathecally administered alpha2-adrenoceptor agonists produce effective antinociception, but sedation is an important adverse effect. Radolmidine is a novel alpha2-adrenoceptor agonist with a different pharmacokinetic profile compared with the well-researched dexmedetomidine. This study determined the antinociceptive and sedative effects of radolmidine in different models of acute and chronic pain. Dexmedetomidine and saline served as controls. METHODS: RESULTS: CONCLUSIONS:
|
Authors | M Xu, V K Kontinen, E Kalso |
Journal | Anesthesiology
(Anesthesiology)
Vol. 93
Issue 2
Pg. 473-81
(Aug 2000)
ISSN: 0003-3022 [Print] United States |
PMID | 10910498
(Publication Type: Comparative Study, Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Adrenergic alpha-Agonists
- Imidazoles
- Indans
- Dexmedetomidine
- radolmidine
|
Topics |
- Adrenergic alpha-Agonists
(administration & dosage, pharmacokinetics, pharmacology)
- Animals
- Area Under Curve
- Constriction
- Dexmedetomidine
(administration & dosage, pharmacokinetics, pharmacology)
- Imidazoles
(metabolism)
- Indans
(metabolism)
- Inflammation
(drug therapy)
- Injections, Spinal
- Male
- Models, Biological
- Motor Activity
(drug effects)
- Pain
(drug therapy)
- Rats
- Rats, Sprague-Dawley
- Spinal Nerves
- Structure-Activity Relationship
|